[1] 文世林. 糖尿病流行的全球趋势和国内现状. 河南诊断与治疗杂志, 2002, 16(1): 14–17.

[2] 李延兵, 翁建平, 许雯, 陈小华, 廖志红, 姚斌, 邓婉萍, 欧香忠, 胡国亮. 短期持续胰岛素输注治疗对初诊2型糖尿病患者胰岛β细胞功能的影响. 中国糖尿病杂志, 2003, 11(1): 10–15.

[3] Nishimura T, Nakatake Y, Konishi M, Itoh N. Identifica-tion of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim Biophys Acta, 2000, 1492(1): 203–206.

[4] Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ, Sandusky GE, Hammond LJ, Moyers JS, Owens RA, Gromada J, Brozinick JT, Haw-kins ED, Wroblewski VJ, De-Shan Li,Mehrbod F, Jas-kunas SR, Shanafelt AB. FGF- 21 as a novel metabolic regulator. J Clin Invest, 2005, 115(6): 1627–1635.

[5] Ausubel FM, Brent R, Kingston RE, Moore DD, Seidman JG, SmithJ A, Strum K. Short Protocols in Molecular Biology, 3rd ed. Boston: John Wiley＆Sons, Inc, 1992, 652–658.

[6] Sambrook J, Fritsch EF, Manutus T. Mogecular Cloning, ALaboratory Manual, 2nd ed. New York: Cold Spring Harbor Laboratory Press, 1989, 9880–9898.

[7] 姜媛媛, 刘铭瑶, 任桂萍, 王文飞, 刘晓民, 李德山. 鼠源成纤维细胞生长因子-21对脂肪细胞糖代谢的作用. 生物化学与生物物理进展, 2009, 36(2): 157–164.

[8] Butt TR, Edavettal SC, Hall JP, Mattern MR. SUMO fu-sion technology for difficult-to-express proteins. Protein Expr Purif, 2005, 43(1): 1–9.

[9] Zuo X, Li S, Hall J, Mattern MR, Tran H, Shoo J, Tan R, Weiss SR, Butt TR. Enhanced expression and purification of membrane proteins by SUMO fusion in Escherichia coli. Struct Funct Gen, 2005, 6(2–3): 103–111.

[10] Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics, 2007, 8(2): 113–128.

[11] Kayano T, Burant CF, Fukumoto H, Gould GW, Fan YS, Eddy RL, Byers MG, Shows TB, Seino S, Bell GI. Human facilitative glucose transporters. J Biol Chem, 1990, 265(22): 13276–13282.

[12] Bell GI, Kayano T, Bose JB, Burant CF, Takeda J, Lin D, Fukumoto H, Seino S. Molecular biology of mammalian glucose transporters. Diabetes Care, 1990, 13 (3): 198–208.

[13] Kharitonenkov A, Wroblewski VJ, Koester A, Chen YF, Clutinger CK, Tigno XT, Hansen BC, Shanafelt AB, Et-gen GJ. The metabolic state of diabetic monkeys is regu-lated by fibroblast growth factor- 21. Endocrinology, 2007, 148(2): 774–781.

[14] Kharitonenkov A, Shanafelt AB. Fibroblast growth fac-tor-21 as a therapeutic agent for metabolic diseases. Biodrugs, 2008, 22 (1): 37-44.

[15] Melchior WR, Jaber LA. Metformin: an antihyperglyce-mic agent for treatment of type II diabetes. Ann Pharma-cother, 1996, 30(2): 158–164.

[16] Campbell LK, White JR, Campbell RK. Acarbose: its role in the treatment of diabetes mellitus. Ann Pharmacother, 1996, 30(11): 1255–1262.

[17] Malakhov MP, Mattern MR, Malakhova OA, Drinker M, Weeks SD, Butt TR. SUMO fusions and SUMO-specific protease for efficient expression and purification of pro-teins. J Struct Funct Genomics, 2004, 5(1–2): 75–86.

[18] Zuo X, Mattern MR, Tan R, Li S, Hall J, Sterner DE, Shoo J, Tran H, Lim P, Sarafianos SG, Kazi L, Navas-Martin S, Weiss SR, Butt TR. Expression and purification of SARS coronavirus proteins using SUMO fusions. Protein Expr Purif, 2005, 42(1): 100–110.

[19] Wang H, Xiao Y, Fu L, Zhao H, Zhang Y, Wan X, Qin Y, Huang Y, Gao H, Li X. High-level expression and purifica-tion of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol, 2010, 10: 14.

[20] 杨桂枝, 高小平, 晏菊芳, 欧可群. GOD-POD法微量化测定方法的建立及其在3T3-L1脂肪细胞和HepG2细胞糖摄取中的应用. 四川解剖学杂志, 2003, 11(1): 12–15.

[21] Khan AH, Pessin JE. Insulin regulation of glucose uptake: a complex interplay of intracellular signalling pathways. Diabetologia, 2002, 45(11): 1475–1483.